Market Place
Sourcing Support
Biofrontera Reports Q3 & Nine-Month 2024 Financial Results & Update
13 Nov 2024 //
GLOBENEWSWIRE
Biofrontera Reports Phase 3 Ameluz®-PDT Results for sBCC
31 Oct 2024 //
GLOBENEWSWIRE
Biofrontera Announces Database Lock Of Ph 3 Study Of sBCC Carcinoma
14 Oct 2024 //
GLOBENEWSWIRE
FDA Approves Up To Three Tubes Of Biofrontera`s Ameluz Per Treatment
07 Oct 2024 //
GLOBENEWSWIRE
Biofrontera Reports Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
09 Aug 2024 //
ACCESSWIRE
Biofrontera Launches FDA-Approved RhodoLED® XL Red Light Source
24 Jun 2024 //
GLOBENEWSWIRE
Biofrontera Reports Q1 2024 Financials, Business Update
15 May 2024 //
ACCESSWIRE
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
06 May 2024 //
ACCESSWIRE
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results
15 Mar 2024 //
ACCESSWIRE
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results
15 Mar 2024 //
ACCESSWIRE
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million
23 Feb 2024 //
ACCESSWIRE
Biofrontera Inc. to Report Third Quarter 2023 Financial Results
03 Nov 2023 //
ACCESSWIRE
Biofrontera Appoints Samantha Widdicombe to Support Commercial Relationships
29 Aug 2023 //
ACCESSWIRE
Biofrontera Announces Last Patient Enrolled in Ph 3 Study Evaluating Ameluz-PDT
10 Aug 2023 //
ACCESSWIRE
Biofrontera Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings
12 Jun 2023 //
ACCESSWIRE
Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as CEO
30 May 2023 //
ACCESSWIRE
Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy
15 May 2023 //
ACCESSWIRE
Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023
28 Apr 2023 //
ACCESSWIRE
Biofrontera Inc. Makes Transformative Investment in Its` Dermatology Salesforce
27 Mar 2023 //
ACCESSWIRE
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting
17 Mar 2023 //
ACCESSWIRE
Biofrontera Reports Fourth Quarter and Record Full-year 2022 Financial Results
08 Mar 2023 //
ACCESSWIRE
Biofrontera to Present at the 35th Annual ROTH Conference on March 13, 2023
02 Mar 2023 //
ACCESSWIRE
Biofrontera Inc. to Report Fourth Quarter and Full Year 2022 Financial Results
22 Feb 2023 //
ACCESSWIRE
Biofrontera, Inc. to Present at Third Annual Winter Wonderland
15 Feb 2023 //
ACCESSWIRE
Biofrontera Announces Voting Results from 2022 Annual Meeting of Stockholders
16 Dec 2022 //
GLOBENEWSWIRE
Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery
30 Nov 2022 //
GLOBENEWSWIRE
Biofrontera To Participate In Renmark’S Non-Deal Roadshow Series in November
28 Nov 2022 //
GLOBENEWSWIRE
Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz-PDT
22 Nov 2022 //
GLOBENEWSWIRE
Biofrontera Reports 3Q 2022 Financial Results and Provides a Business Update
14 Nov 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Fully Exercises Recently Acquired Options to Purchase Shares
08 Nov 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
31 Oct 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Names Fred Leffler as Chief Financial Officer
24 Oct 2022 //
GLOBENEWSWIRE
Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference
20 Oct 2022 //
GLOBENEWSWIRE
Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference
18 Oct 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
14 Oct 2022 //
GLOBENEWSWIRE
BIOFRONTERA INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES
12 Oct 2022 //
GLOBENEWSWIRE
Biofrontera Inc. to Present at the Roth Inaugural Healthcare
29 Sep 2022 //
GLOBENEWSWIRE
Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360
26 Sep 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
13 Sep 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion U.S. Patent
06 Sep 2022 //
GLOBENEWSWIRE
Biofrontera Named PM360 Trailblazer 2022 Brand Champion for Dermatology
18 Aug 2022 //
GLOBENEWSWIRE
Biofrontera Announces Patent in Australia for Novel Illumination Protocols
01 Aug 2022 //
GLOBENEWSWIRE
Biofrontera Announces Exercise of Existing Warrants and Issuance of Warrants
27 Jul 2022 //
GLOBENEWSWIRE
Biofrontera Announces Preliminary Product Revenues for Q2 2022
12 Jul 2022 //
GLOBENEWSWIRE
Biofrontera Recognized for Rapid Sales Growth, Therapies and Market Excellence
09 Jun 2022 //
GLOBENEWSWIRE
Biofrontera to Participate in The Benchmark Healthcare Conference
31 May 2022 //
GLOBENEWSWIRE
New Data and Forecasts for Strongly Support Biofrontera`s Ameluz
24 May 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Announces Closing of $9.4 Million Private Placement
19 May 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement
16 May 2022 //
GLOBENEWSWIRE
Biofrontera Inc. Reports First Quarter 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
BioFrontera bows bold imagery websites amid Q1 sales gains in dermatology
13 May 2022 //
ENDPTS
Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022
06 May 2022 //
GLOBENEWSWIRE
Biofrontera to Showcase Actinic Keratosis Treatments
05 May 2022 //
GLOBENEWSWIRE
Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®
21 Apr 2022 //
GLOBENEWSWIRE
Biofrontera Bags FDA Approval of Biofrontera as Contract Laboratory for Ameluz
13 Apr 2022 //
GLOBENEWSWIRE
Biofrontera Reports Fourth Quarter and Full Year 2021 Financial Results
08 Apr 2022 //
GLOBENEWSWIRE
Biofrontera Announces Prelim Product Revenues for the First Quarter of 2022
06 Apr 2022 //
GLOBENEWSWIRE
Biofrontera to Q4 and Full Year 2021 Financial Results on April 8, 2022
01 Apr 2022 //
GLOBENEWSWIRE
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments
17 Mar 2022 //
GLOBENEWSWIRE
